|
Mark Enyedy joined Genzyme in 1996. He is responsible for day-to-day management and strategic planning for the product portfolio of Genzyme’s cancer therapeutics business unit and for the company's multiple sclerosis program. He is also responsible for managing the unit’s mergers and acquisitions product acquisition and corporate partnering transactions.
Before joining Genzyme Mr. Enyedy practiced law at Palmer & Dodge a Boston law firm where he represented a number of clients in the biopharmaceutical industry in acquisition partnering and financing transactions.Mr. Enyedy received a J.D. from Harvard Law School and a B.S. from Northeastern University. | 